Twist Bioscience has received $26 million in Series B financing. The round was led by Tao Invest, and received participation from ARCH Venture Partners and Paladin Capital Group. Earlier this year, the company raked in $9 million in Series A funds, valuing the company at over $17 million. The new venture funding will be used to commercialize the company's semiconductor-based synthetic gene manufacturing process. As part of a separate transaction, the company also received a $5.1 million contract from the Defense Advanced Research Projects Agency to fund development of Twist's tech platform for large-scale, high-throughput construction of genetic designs.